Written by: Cole Maguire Edited by: Esther Melamed Throughout the course of the COVID-19 pandemic, it has been recognized that a number of pressing secondary pathologies often develop in patients with severe COVID-19 disease. One of these secondary pathologies is COVID Associated Coagulopathy (CAC), which results in an over-abundance of clotting in the body and can contribute to strokes, heart attacks, and deep vein thrombosis. In order to combat this clotting, blood thinners, such as heparin are being tested in several trials, including ACTIV-4, REMAP-CAP, and ATTACC, to evaluate whether …